Central Research and Development Laboratory relocated to newly completed facilities in yongin city

Co-promotion & Distribution Agreement with GSK(REQUIP, REQUIP PD, IMIGRAN, NARAMIG, PAXIL CR, WELLBUTRIN XL, SEROXAT)

Received approval as the first individually recognized functional material related to persimmon leaf alcohol extract and xerophthalmia

Acquired certification of Quality Management System ‘ISO 9001’

Signed a contract to take Hyangnam Plant in Janssen, Korea

Subsidiary Company, AsYou Co., Ltd. was founded

License & Distribution Agreement with Gedeon Richter (REAGILA)

Joint Agreement with Ybrain for a wireless EEG system MINDD SCAN

Acquired certification of Anti-bribery Management System ‘ISO37001’

Co-promotion Agreement with GSK KOREA (REQUIP, LAMICTAL, NARAMIG, IMIGRAN)

Seoul Research Institute was established

Product Registration and Distribution Agreement with MYLAN (CLOZARIL)

Export to Turkey

Subsidiary Company, AMBRO B&P Co., Ltd was founded

40th Foundation Anniversary Ceremony was held

Export to Yemen

License and Distribution Agreement with Bial (ZEBINIX)

Supply Agreement with Les Laboratories Servier (ARGOTIN)

Munjeong-dong building transferred (to 11 6-Gil, Beopwon-Ro, Songpa-gu)

Export to Mongolia

Distribution and Promotion Agreement with Sandoz Korea (MIRTAX)

Distribution and Promotion Agreement with Sandoz Korea (Fluconazole, Amlodipine)

Distribution and Promotion Agreement with Allergan Korea (BOTOX, JEVEDERM)

Products Distribution and Promotion Agreement with Abbott Korea (DEPAKOTE)

Distribution Agreement with Shire Ireland (METADATECD)

Distribution and Promotion Agreement with Sandoz Korea (Escitalopram, Sertraline and Paroxeitne)

CEO&President Wonbum Lee was appointed as the fifth head of the company

Risperidone achieved 10 billion Won annual sales

An agreement was made with KIOM on obesity medication technology transfer

Co-promotion & Distribution Agreement with Lundbeck Korea (Nalmefene)

Central Research Institute transferred (GBSA)

Antidepressant medication Lexapro achieved 10 billion Won sales

Exclusive Distribution & License Agreement with Labopharm (TRAMACONTI)

Anseong Factory was renovated

Co-promotion agreement with Lundbeck Korea (CIPRAM)

President Kyekwan Lee was appointed as the fourth head of the company

Co-promotion agreement with Lundbeck Korea (LEXAPRO)

Designated as excellent KGMP company (by Gyeongin Regional MFDS)

President Keunglim Kim was appointed as the third head of the company

Received Excellent Enterprise of New Labor Management Culture Award (by the Minister of Labor)

Whanin Psychiatry Award was established

Designated as Korean Good Supplying Practice (KGSP) eligible company

President Hoil Park was appointed as the second head of the company

Central Research Institute was established

Export to Singapore and Vietnam initiated

Whanin was disclosed to Korea Exchange

Central Research Institute was founded

Export to Pakistan initiated

Company building transferred to Munjeong-dong (117 Saemal-ro, Songpa-gu)

Anseong Factory was designated as KGMP eligible company (by the Ministry of Health and Society)

Anseong KGMP factory was established (Site area: 4,269.22m2)

The company incorporated to Whan In Pharm. Co., Ltd.

Anam-dong Building was established

Whanin was founded under Chairman Gwangsik Lee (Jeongneung-dong Building: Head office / Factory)